Pohlmann-Eden B, Stephani U, Krägeloh-Mann I, Schmitt B, Brandl U, Holtkamp M
Epilepsie-Zentrum Bethel, Evangelisches Krankenhaus Bielefeld, Bielefeld, Germany.
Nervenarzt. 2007 Aug;78(8):871-82. doi: 10.1007/s00115-007-2257-5.
Status epilepticus is a frequent neurologic emergency that is refractory to benzodiazepines and phenytoin in 60% to 70% of cases. Patients commonly require management in an intensive care unit incorporating aggressive treatment with intravenous anaesthetics. Treatment guidelines commonly comment on initial pharmacologic management in detail, as they can refer to data from randomised controlled trials. In contrast, recommendations for the management of refractory status epilepticus often are sparse, as they rely on data from retrospective or uncontrolled prospective studies only. Since status epilepticus is refractory in every third patient, a critical analysis of the available data and a review focussing on the further management of this condition are urgently needed. The Koenigstein Team, a panel of expert epileptologists and neuropediatricians, discussed at its 31(st) meeting in March 2006 the clinical and experimental aspects and implicit prognostic variables of refractory status epilepticus. Here we present the results of that discussion and state recommendations from a neurologic and neuropediatric perspective for current und future management of refractory status epilepticus.
癫痫持续状态是一种常见的神经系统急症,60%至70%的病例对苯二氮卓类药物和苯妥英钠治疗无效。患者通常需要在重症监护病房接受治疗,采用静脉麻醉剂进行积极治疗。治疗指南通常会详细阐述初始药物治疗,因为它们可以参考随机对照试验的数据。相比之下,关于难治性癫痫持续状态治疗的建议往往很少,因为这些建议仅依赖于回顾性或非对照前瞻性研究的数据。由于每三分之一的癫痫持续状态患者治疗无效,因此迫切需要对现有数据进行批判性分析,并针对该病症的进一步治疗进行综述。柯尼希施泰因团队由癫痫专家和神经儿科专家组成,在2006年3月的第31次会议上讨论了难治性癫痫持续状态的临床和实验方面以及隐含的预后变量。在此,我们展示该讨论的结果,并从神经学和神经儿科学的角度阐述关于难治性癫痫持续状态当前及未来治疗的建议。